Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/7/2025

Management of Testosterone-Induced Erythrocytosis Before Surgery

Understanding Testosterone-Induced Erythrocytosis

  • Testosterone therapy commonly causes erythrocytosis, particularly with injectable formulations, which are associated with a 43.8% risk of elevated hematocrit values, according to the New England Journal of Medicine 1, 2
  • A patient's hemoglobin and hematocrit levels, such as 17.5 g/dL and 50%, indicate significant erythrocytosis that requires intervention before surgery, as reported in the New England Journal of Medicine 3

Risks of Proceeding with Surgery

  • Elevated hematocrit increases blood viscosity, which can aggravate vascular disease in coronary, cerebrovascular, or peripheral circulation, particularly in older patients, as noted in the New England Journal of Medicine 2

Pre-Surgical Management Algorithm

  • The American Heart Association recommends phlebotomy for adults with hematocrit >65% before noncardiac surgery, but for patients on testosterone therapy, intervention at lower thresholds (>50%) is warranted, according to Circulation 4
  • Perform therapeutic phlebotomy to reduce hematocrit below 50% before surgery, as recommended in Circulation 4
  • Ensure adequate hydration perioperatively to prevent further hemoconcentration, as advised in the New England Journal of Medicine 3
  • Assess for other cardiovascular risk factors that may compound the risk, as suggested in The Journal of Urology 5

Post-Surgical Considerations

  • Resume testosterone therapy only after full recovery and with a modified regimen, as recommended in the New England Journal of Medicine 1
  • Consider switching from injectable to topical testosterone preparations, which have lower rates of erythrocytosis, such as 5.5% for transdermal patches vs. 43.8% for injections, according to the New England Journal of Medicine 1

Special Considerations for Older Patients

  • Patients in their mid-50s have higher baseline cardiovascular risk, making testosterone-induced erythrocytosis potentially more dangerous, as reported in the New England Journal of Medicine 2